MAGEA3 and melanoma: The data from the phase 2 randomized NSCLC trial and patients with melanoma encouraged and moved the MAGEA3 immunotherapeutic forward (48, 49), while DERMA and MAGRIT which are phase III clinical trials indicated that MAGEA3 immunotherapeutic did not benefit overall survival or disease-free survival of patients with NSCLC or melanoma (26, 27).